Literature DB >> 17264499

Intermediate and posterior uveitis.

John V Forrester1.   

Abstract

Sight-threatening intraocular inflammation affecting the posterior segment of the eye may be predominantly located in the peripheral retina and vitreous (intermediate uveitis) or postequatorially where it manifests as inflammation of the retina, retinal vessels and/or optic nerve with cellular infiltration of the choroid and retina and edema particularly at the macula. Involvement of the macula is the main cause for visual loss. Experimental models of posterior uveitis have revealed much concerning the mechanisms of inflammatory cell damage to the retina, implicating CD4 T cells, effector macrophages and pro-inflammatory cytokines. In particular, transgenic and gene deletion models of inflammation have allowed an understanding of how immune privilege in the posterior segment of the eye is disrupted. Importantly, this has led to the development of new treatments with novel immunosuppressants and 'biologics' and the promise of cell-based therapies which may allow customized therapies tailored to the individual's inflammatory profile.

Entities:  

Mesh:

Year:  2007        PMID: 17264499     DOI: 10.1159/000099274

Source DB:  PubMed          Journal:  Chem Immunol Allergy        ISSN: 0079-6034


  14 in total

1.  In-vivo and ex-vivo characterization of laser-induced choroidal neovascularization variability in mice.

Authors:  Robert Hoerster; Philipp S Muether; Sarah Vierkotten; Susanne Schröder; Bernd Kirchhof; Sascha Fauser
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-16       Impact factor: 3.117

2.  Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms.

Authors:  Hyun-Mee Oh; Cheng-Rong Yu; Yongjun Lee; Chi-Chao Chan; Arvydas Maminishkis; Charles E Egwuagu
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

3.  Novel IL27p28/IL12p40 cytokine suppressed experimental autoimmune uveitis by inhibiting autoreactive Th1/Th17 cells and promoting expansion of regulatory T cells.

Authors:  Ren-Xi Wang; Cheng-Rong Yu; Rashid M Mahdi; Charles E Egwuagu
Journal:  J Biol Chem       Date:  2012-08-30       Impact factor: 5.157

4.  Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.

Authors:  Rajwahrdhan Yadav; Sourojit Bhowmick; Philip Gorecki; James O'Rourke; Robert E Cone
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

5.  Bowman lecture on the role of inflammation in degenerative disease of the eye.

Authors:  J V Forrester
Journal:  Eye (Lond)       Date:  2013-01-04       Impact factor: 3.775

Review 6.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

7.  Morphometric features on enhanced depth imaging optical coherence tomography scans in idiopathic posterior uveitis or panuveitis.

Authors:  Rupesh Agrawal; Rashi Arora; Pearse A Keane; Aniruddha Agarwal; Carlos Pavesio
Journal:  Int Ophthalmol       Date:  2017-06-05       Impact factor: 2.031

8.  AAV2-mediated combined subretinal delivery of IFN-α and IL-4 reduces the severity of experimental autoimmune uveoretinitis.

Authors:  Lichun Tian; Bo Lei; Ju Shao; Lin Wei; Aize Kijlstra; Peizeng Yang
Journal:  PLoS One       Date:  2012-06-07       Impact factor: 3.240

9.  Therapeutic targeting of STAT3 (signal transducers and activators of transcription 3) pathway inhibits experimental autoimmune uveitis.

Authors:  Cheng-Rong Yu; Yun Sang Lee; Rashid M Mahdi; Narayanan Surendran; Charles E Egwuagu
Journal:  PLoS One       Date:  2012-01-05       Impact factor: 3.240

10.  Tumor necrosis factor polymorphisms associated with tumor necrosis factor production influence the risk of idiopathic intermediate uveitis.

Authors:  Denize Atan; Jarka Heissigerova; Lucia Kuffová; Aideen Hogan; Dara J Kilmartin; John V Forrester; Jeff L Bidwell; Andrew D Dick; Amanda J Churchill
Journal:  Mol Vis       Date:  2013-01-28       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.